Biogen Idec (BIIB) Submits BLA to FDA for rFVIIIFc as Hemophilia A Treatment
Tweet Send to a Friend
Biogen Idec, Inc. (Nasdaq: BIIB) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
